利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.014 秒)

    Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
    1.
    发明申请
    Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) 审中-公开
    肝素结合蛋白（hbp）的细菌抗细胞凋亡，促炎症和抗炎肽

    公开(公告)号：US20060173162A1

    公开(公告)日：2006-08-03

    申请号：US10524434

    申请日：2003-08-14

    申请人： Rene Djurup ,  Hans Flodgaard ,  Kjeld Norris

    发明人： Rene Djurup ,  Hans Flodgaard ,  Kjeld Norris

    IPC分类号： A61K38/16 ,  C07K14/195

    CPC分类号： C07K14/4723 ,  A61K38/00

    摘要： The present invention relates to providing new peptide fragments derived from the sequence of heparin-binding protein (HBP) and/or human neutrophil elastase and using said fragments for the manufacture of a medicament for the treatment of Gram positive and/or Gram negative infections. Thus, the peptides of the inventions can be used for treatment of pneumonia and/meningitis. The peptides of the invention may also be advantageously used for the treatment of any pathological condition demanding modulating of inflammatory response and/or a condition involving sepsis and/or, disseminated intravascular coagulation. Among other pathological conditions, which may be regarded for the treatment with the peptides of the invention, are conditions involving cell apoptosis.

    摘要翻译： 本发明涉及提供源自肝素结合蛋白（HBP）和/或人嗜中性粒细胞弹性蛋白酶序列的新的肽片段，并使用所述片段制备用于治疗革兰氏阳性和/或革兰氏阴性感染的药物。 因此，本发明的肽可用于治疗肺炎和脑膜炎。 本发明的肽还可有利地用于治疗需要调节炎症反应和/或涉及败血症和/或弥漫性血管内凝血的病症的任何病理状况。 在本发明的肽中可以考虑用于治疗的其它病理状况是涉及细胞凋亡的病症。

    Inhibition of bradykinin release
    2.
    发明申请
    Inhibition of bradykinin release 审中-公开
    抑制缓激肽释放

    公开(公告)号：US20060154319A1

    公开(公告)日：2006-07-13

    申请号：US11248110

    申请日：2005-10-11

    申请人： Hans Flodgaard ,  Lennart Lindbom ,  Soren Bjorn

    发明人： Hans Flodgaard ,  Lennart Lindbom ,  Soren Bjorn

    IPC分类号： A61K38/17 ,  G01N33/537 ,  G01N33/53 ,  G01N33/543

    CPC分类号： A61K38/57 ,  G01N33/5064 ,  G01N2333/575 ,  G01N2333/96433

    摘要： The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal a HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to a HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP.

    摘要翻译： 本发明涉及用于治疗或预防所述哺乳动物，特别是产生结合HBP拮抗剂的HBP的哺乳动物例如缓释肽释放引起的疾病的方法，例如， 与人类HBP的至少一个表位结合的单克隆抗体，包括向所述哺乳动物施用有效降低哺乳动物缓激肽释放量的HBP拮抗剂。 此外，本发明涉及用于确定哺乳动物是否产生结合HBP拮抗剂的HBP的方法和试剂盒，例如与人HBP的至少一个表位结合的单克隆抗体和检测HBP拮抗剂的方法。

    Pro-Inflammatory and Anti-Inflammatory Antibodies Against the Heparin-Binding Protein (Hbp)
    3.
    发明申请
    Pro-Inflammatory and Anti-Inflammatory Antibodies Against the Heparin-Binding Protein (Hbp) 审中-公开
    用于肝素结合蛋白（Hbp）的促炎和抗炎抗体

    公开(公告)号：US20070269437A1

    公开(公告)日：2007-11-22

    申请号：US10572603

    申请日：2004-09-17

    申请人： Rene Djurup ,  Hans Flodgaard ,  Kjeld Norris

    发明人： Rene Djurup ,  Hans Flodgaard ,  Kjeld Norris

    IPC分类号： A61K39/395 ,  A61P29/00 ,  C12P21/08

    CPC分类号： C07K16/18 ,  A61K2039/505

    摘要： The present invention relates to providing antibodies against human heparin-binding protein (hHBP) or against a homologue of hHBP, such as porcine heparin binding protein (pHBP) or human neutrophil elastase (hNEL), and using said antibodies for the manufacture of a medicament for treatment of Gram positive and/or Gram negative infections, sepsis, disseminated intravascular coagulation, modulation of inflammatory response, and/or prevention of cell apoptosis. Antibodies of the invention are capable of modulating at least one inflammatory response associated with hHBP, in particular, the invention relates to monoclonal antibody F19A5B1, capable of stimulating said at least one inflammatory response, and monoclonal antibody F19A5B4, capable of inhibiting said at least one inflammatory response.

    摘要翻译： 本发明涉及提供针对人肝素结合蛋白（hHBP）的抗体或针对hHBP的同系物，例如猪肝素结合蛋白（pHBP）或人嗜中性粒细胞弹性蛋白酶（hNEL）），并且使用所述抗体制备药物 用于治疗革兰氏阳性和/或革兰氏阴性感染，败血症，弥散性血管内凝血，调节炎症反应和/或预防细胞凋亡。 本发明的抗体能够调节与hHBP相关的至少一种炎性反应，特别地，本发明涉及能够刺激所述至少一种炎症反应的单克隆抗体F19A5B1，以及能够抑制所述至少一种抗体的单克隆抗体F19A5B4 炎症反应。

    Pharmaceutical composition
    5.
    发明授权
    Pharmaceutical composition 失效
    药物组成

    公开(公告)号：US5939390A

    公开(公告)日：1999-08-17

    申请号：US925708

    申请日：1997-09-09

    申请人： Hans Flodgaard ,  Poul Baad Rasmussen

    发明人： Hans Flodgaard ,  Poul Baad Rasmussen

    IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K14/47

    CPC分类号： A61K47/48023 ,  A61K47/48046 ,  C07K14/4723 ,  A61K38/00 ,  Y10S530/829

    摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of diseases or conditions involving stress injury to cells, the composition comprising(a) a lipid-containing substance having a lipid portion which is structurally identical with or analogous to a ceramide, conjugated to(b) a protein capable of binding said lipid-containing substance in such a way that, when the conjugate is contacted with living cells, the lipid-containing substance activates a ceramide-activated protein phosphatase resulting in down-regulation of cellular metabolism, and(c) a pharmaceutically acceptable diluent or carrier.

    摘要翻译： 本发明涉及用于预防或治疗涉及对细胞的应激损伤的疾病或病症的药物组合物，该组合物包含（a）具有与神经酰胺结构相似或相似的脂质部分的含脂物质， 至（b）能够结合所述含脂物质的蛋白质，使得当缀合物与活细胞接触时，含脂物质激活神经酰胺活化蛋白磷酸酶，导致细胞代谢的下调， 和（c）药学上可接受的稀释剂或载体。